Tiziana Life Sciences Ltd (TLSA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol TLSA
- Company Tiziana Life Sciences Ltd
- Price $0.97
- Changes Percentage 25.96
- Change 0.1999
- Day Low $0.85
- Day High $1.01
- Year High $2.35
- Year Low $0.87
- Market Cap $72,537,700
- Price Avg 50 EMA (D) $1.1
- Price Avg 200 EMA (D) $1.37
- Exchange NASDAQ
- Volume 830,428
- Average Volume 520,293
- Open $0.85
- Previous Close $0.77
- EPS -0.32
- PE -3.60
- Earnings Announcement 2026-09-18 12:00:00
- Shares Outstanding $63,629,561
Company brief: TIZIANA LIFE SCIENCES LTD (TLSA )
- Healthcare
- Biotechnology
- Mr. Gabriele Marco Antonio Cerrone M.B.A.
- https://www.tizianalifesciences.com
- GB
- N/A
- 11-20-2018
- BMG889121031
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.